Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Minimizing ciclosporin in renal transplant recipients on daclizumab, mycophenolate and steroids

Nature Clinical Practice Nephrology volume 3, pages 426–427 (2007)Cite this article

boxed-textEkberg H et al. (2007) Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant 7: 560–570

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Danovitch GM (2004) Immunosuppressive medications and protocols for kidney transplantation. In Handbook of Kidney Transplantation, edn 4 72–134 (Ed. Danovitch GM) Philadelphia: Lippincott Williams & Wilkins

    Google Scholar 

  2. Meier-Kriesche HU et al. (2003) Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 75: 1291–1295

    Article  Google Scholar 

  3. Nankivell BJ et al. (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326–2333

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. in the Division of Nephrology of the David Geffen School of Medicine, S Bunnapradist is Associate Professor of Medicine and Director of Clinical Research for the Kidney Transplant Program, and GM Danovitch is Professor of Medicine and Medical Director of the Kidney and Pancreas Transplant Program, University of California, Los Angeles, CA, USA.,

    Suphamai Bunnapradist & Gabriel M Danovitch

Authors
  1. Suphamai Bunnapradist
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriel M Danovitch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suphamai Bunnapradist.

Ethics declarations

Competing interests

S Bunnapradist declared no competing interests. GM Danovitch has received grants/research support from Fujisawa, Novartis and Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bunnapradist, S., Danovitch, G. Minimizing ciclosporin in renal transplant recipients on daclizumab, mycophenolate and steroids. Nat Rev Nephrol 3, 426–427 (2007). https://doi.org/10.1038/ncpneph0540

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0540

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing